[ A23-106] Axicabtagene ciloleucel (DLBCL and HGBL, second line) – Addendum to Commission A23-66

Last updated 21.12.2023

Project no.:
A23-106

Commission:
Commission awarded on 08.11.2023 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Topic:
Cancer

Indication:

Adults with diffuse large B-cell lymphoma or high-grade B-cell lymphoma that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy

Result of dossier assessment:
  • If high-dose therapy is an option: Unchanged after addendum: added benefit not proven
  • If high-dose therapy is not an option: Unchanged after addendum: added benefit not proven
Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

DOI:

https://dx.doi.org/10.60584/A23-106

Federal Joint Committee (G-BA)

2023-12-21 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form